Please try another search
For the nine months ended 30 September 2019, SiennaBiopharmaceuticals Inc revenues was not reported. Net lossdecreased 47% to $28.6M. Lower net loss reflects Researchand development - Balancing val decrease of 63% to $14.9M(expense). Basic Earnings per Share excluding ExtraordinaryItems increased from -$2.66 to -$1.07.
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -8.04 | -7.73 | -15.84 | -19.77 |
Net Income | -3.97 | -8.26 | -16.38 | -19.34 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 43.49 | 107.62 | 115.05 | 107.31 |
Total Liabilities | 20.39 | 80.64 | 81.77 | 80.72 |
Total Equity | 23.1 | 26.98 | 33.29 | 26.58 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -39.03 | -21.19 | -12.77 | -61.69 |
Cash From Investing Activities | -0 | -0 | -0 | -0.04 |
Cash From Financing Activities | 1.88 | 21.88 | 21.43 | 35.96 |
Net Change in Cash | -37.16 | 0.68 | 8.64 | -25.94 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review